Yesterday afternoon I was elbow-deep in a bowl of soaked oats when my neighbor Marnie texted me a screenshot with three exclamation points and a skull emoji, which is how I receive almost all of my medical news now. The FDA had approved a new non-opioid pain pill called Journavx. I read the name out loud twice. I read it out loud a third time to my husband, Garrett, who was feeding the chickens. Journavx. Go ahead and try it. Your mouth knows.
I am not, as I’ve said before, anti-medicine. I took a Tylenol once in 2019 and wrote about it for six weeks. What I am is a mother of four who has learned to listen when the body in front of me — mine, or one of my children’s, or the goat — tells me something isn’t right. And a word with a silent J, a runaway V, and an X that just shows up uninvited at the end like a stepdad is, to my gut, not right.
I did what any responsible person would do, which is post the headline in my Facebook group (Seed Oils and the Lies They Told Us, which has recently expanded scope to include most pharmaceutical naming conventions). Within nine minutes a woman named Tabitha from somewhere outside Spokane pointed out that Journavx is an anagram, almost, of “van jar ox,” and while I don’t know exactly what to do with that, I don’t love it. Tabitha is a former veterinary assistant and, I believe, currently writes a Substack called The Body Keeps the Receipt.
My sister-in-law Hollis, who works the front desk at a pediatric office in Hendersonville and is basically a nurse at this point, sent me a voice memo about it while she was picking up her oldest from jazz band. She said — and I’m quoting — “Brooke, they already have something for pain. It’s called a warm castor oil pack. It’s called magnesium. It’s called actually going to bed at nine.” She also said something about how the approval was rushed, which I can’t confirm, but Hollis has been right about three separate things since October, including the thing with the yogurt.
Here is what I keep coming back to, and I want to say this gently. Pain is information. Pain is your body tapping on the glass. When we numb the tap, the body just taps harder somewhere else — in my experience, usually the jaw, then the hips, then eventually the mood. I learned this from a podcast called The Fascia Hour, hosted by a man named Dr. Rowan Beckett, DC, CNT, whose credentials I have not been able to fully trace but whose vibe is, frankly, correct.
Now, the pitch on Journavx, as I understand it from the article Marnie sent me and then a second article I read with my laptop turned sideways so the blue light wouldn’t hit my pineal gland directly, is that it’s a non-opioid. Great. Wonderful. Truly. But “non-opioid” is what we call in marketing a category exit, not an identity. I worked in brand management for six years before we moved to the homestead. I have sat in the room where men in quarter-zips decide that a molecule needs a name that sounds like a Nordic cruise line. Journavx did not emerge from a meadow. Journavx came out of a conference room in Boston at eleven-forty a.m.
My oldest, Ember, who is nine and has opinions, asked me at dinner last night whether the new pill was “the one for the hurt.” I told her it was, sort of. She chewed her sourdough (36-hour ferment, which I maintain is not an ingredient but a practice) and said, “But we already have ginger.” And listen. I know she’s nine. I know ginger is not, clinically speaking, a substitute for a sodium channel blocker. But I also know that a nine-year-old raised on bone broth and morning light can often see the shape of a thing faster than a grown adult with a subscription to The Atlantic.
I want to be fair to the people who will take this medication, because there are many and I love them. If you have had a surgery, if you are in the kind of pain that doesn’t respond to a walk around the driveway and a tablespoon of raw honey, you are not my target audience and I am sending you only softness. What I’m talking about are the borderline cases. The tension headache at 2 p.m. The back twinge from sleeping on a mattress that, let’s be honest, is off-gassing. For those, please, before you reach for something with an X in it, reach for a hot water bottle and a phone call to your mother.
Garrett, who is more moderate than I am on most of these issues and who once bought ibuprofen at a gas station without telling me, actually agreed when I read him the name out loud. He said, “That sounds like a mid-tier SUV.” Then he said, “Or a Romanian soccer team.” Then he went back outside. This is the closest Garrett gets to an endorsement, and I’m taking it.
I did, in the interest of fairness, try to read the actual prescribing information. I got through about four paragraphs before I hit the word “hepatic” and had to go lie down in the mudroom with a rosemary poultice on my sternum. I don’t think that’s a coincidence. I think the documents themselves carry a frequency, and I think that frequency is, charitably, “don’t.”
So here is where I’ve landed, for now, and I reserve the right to update. If your doctor — and I mean an actual doctor you chose, not one assigned to you by an insurance algorithm — looks at you and says Journavx is the right call, I trust you to make that decision with your own inner knowing. But if the only reason you’re considering it is because a headline popped up between a Reel about sourdough and a Reel about a woman organizing her freezer, I would gently, lovingly, walk you back to the kitchen.
There is a castor oil pack warming on my stove right now. There is a jar of magnesium glycinate on my nightstand. There is a nine-year-old downstairs who thinks ginger is a civilization. I know which pharmacy I’m shopping at. And it doesn’t have an X in the name.